Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Teva/Celltrion's Truxima Is First Biosimilar Rituxan To Reach US Market

07 Nov 2019

• By Jessica Merrill

text 10 percentages discount 3d red white banner, letters and block, business concept — Truxima will launch at a 10% lower WAC than Rituxan • Source: Shutterstock

Related Content

Novartis Gives Up On Rituxan Biosimilar For US Market

05 Nov 2018

FDA Approves Pfizer's Ruxience Rituximab Biosimilar

24 Jul 2019

US Market For Therapeutic Cancer Biosimilars Will Be Tested By Mvasi, Kanjinti Launches

19 Jul 2019

Teva Plugs Gap With Celltrion Deal For Rituxan And Herceptin Biosimilar Candidates

06 Oct 2016

Teva’s 'Key Ingredient' For Growth: Biosimilars

13 Sep 2016

Related Companies

Teva Pharmaceutical Industries Ltd.

Celltrion, Inc.

Roche Holding AG

Pfizer Inc.

Amgen, Inc.

Allergan plc

Additional Topics

Biosimilars Launches Commercial Cancer BioPharmaceutical

More from New Products

More from Scrip

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.